vs
Side-by-side financial comparison of AlTi Global, Inc. (ALTI) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $86.6M, roughly 1.9× AlTi Global, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 87.0%). Over the past eight quarters, AlTi Global, Inc.'s revenue compounded faster (30.6% CAGR vs 10.6%).
Cristal Global is the world's second-largest producer of titanium dioxide and a leading producer of titanium chemicals. It was formed when The National Titanium Dioxide Company Ltd. combined with Millennium Chemicals. The headquarters are in Jeddah, Saudi Arabia. It is a significant shareholder in Bemax, the world’s 5th largest TiO2 feedstock producer.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ALTI vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.6M | $168.4M |
| Net Profit | $-13.1M | — |
| Gross Margin | — | — |
| Operating Margin | -2.1% | 50.6% |
| Net Margin | -15.1% | — |
| Revenue YoY | 87.0% | 143.7% |
| Net Profit YoY | 75.6% | — |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.6M | $168.4M | ||
| Q3 25 | $57.2M | $87.3M | ||
| Q2 25 | $53.1M | $82.4M | ||
| Q1 25 | $58.0M | $65.0M | ||
| Q4 24 | $46.3M | $69.1M | ||
| Q3 24 | $51.8M | $51.6M | ||
| Q2 24 | $49.5M | $73.8M | ||
| Q1 24 | $50.8M | $137.7M |
| Q4 25 | $-13.1M | — | ||
| Q3 25 | $-84.1M | $-31.3M | ||
| Q2 25 | $-24.4M | $-12.7M | ||
| Q1 25 | $1.9M | $-40.5M | ||
| Q4 24 | $-53.8M | — | ||
| Q3 24 | $-72.5M | $-29.5M | ||
| Q2 24 | $-6.4M | $-61.9M | ||
| Q1 24 | $29.7M | $61.0M |
| Q4 25 | -2.1% | 50.6% | ||
| Q3 25 | -49.8% | -11.4% | ||
| Q2 25 | -56.7% | 8.6% | ||
| Q1 25 | -23.3% | -34.0% | ||
| Q4 24 | -42.7% | -6.4% | ||
| Q3 24 | -18.4% | -31.0% | ||
| Q2 24 | -30.2% | 3.5% | ||
| Q1 24 | -28.9% | 52.5% |
| Q4 25 | -15.1% | — | ||
| Q3 25 | -147.0% | -35.9% | ||
| Q2 25 | -45.9% | -15.4% | ||
| Q1 25 | 3.3% | -62.2% | ||
| Q4 24 | -116.1% | — | ||
| Q3 24 | -140.0% | -57.2% | ||
| Q2 24 | -12.9% | -83.9% | ||
| Q1 24 | 58.4% | 44.3% |
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | $-0.33 | $-0.06 | ||
| Q1 25 | $-0.04 | $-0.21 | ||
| Q4 24 | $-0.71 | $-0.14 | ||
| Q3 24 | $-0.88 | $-0.15 | ||
| Q2 24 | $-0.18 | $-0.33 | ||
| Q1 24 | $0.18 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.2M | $167.9M |
| Total DebtLower is stronger | $883.0K | — |
| Stockholders' EquityBook value | $600.1M | $-302.0M |
| Total Assets | $1.2B | $465.9M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $41.2M | $167.9M | ||
| Q3 25 | $35.8M | $92.4M | ||
| Q2 25 | $42.4M | $86.1M | ||
| Q1 25 | $52.8M | $114.6M | ||
| Q4 24 | $64.4M | $144.8M | ||
| Q3 24 | $220.6M | $144.7M | ||
| Q2 24 | $60.0M | $189.3M | ||
| Q1 24 | $134.2M | $226.6M |
| Q4 25 | $883.0K | — | ||
| Q3 25 | $586.0K | — | ||
| Q2 25 | $673.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $128.4M | — | ||
| Q2 24 | $164.0M | — | ||
| Q1 24 | $183.7M | — |
| Q4 25 | $600.1M | $-302.0M | ||
| Q3 25 | $607.2M | $-451.4M | ||
| Q2 25 | $685.4M | $-433.5M | ||
| Q1 25 | $665.2M | $-426.2M | ||
| Q4 24 | $658.4M | $-388.7M | ||
| Q3 24 | $707.0M | $-370.2M | ||
| Q2 24 | $540.2M | $-344.2M | ||
| Q1 24 | $510.9M | $-294.3M |
| Q4 25 | $1.2B | $465.9M | ||
| Q3 25 | $1.2B | $364.0M | ||
| Q2 25 | $1.2B | $347.1M | ||
| Q1 25 | $1.2B | $324.0M | ||
| Q4 24 | $1.3B | $343.8M | ||
| Q3 24 | $1.4B | $314.1M | ||
| Q2 24 | $1.3B | $352.3M | ||
| Q1 24 | $1.3B | $373.1M |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.18× | — | ||
| Q2 24 | 0.30× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-51.4M | $45.2M |
| Free Cash FlowOCF − Capex | $-52.2M | — |
| FCF MarginFCF / Revenue | -60.3% | — |
| Capex IntensityCapex / Revenue | 0.9% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-51.4M | $45.2M | ||
| Q3 25 | $-53.5M | $-4.3M | ||
| Q2 25 | $-19.9M | $-31.4M | ||
| Q1 25 | $-30.2M | $-22.6M | ||
| Q4 24 | $-50.7M | $-35.0M | ||
| Q3 24 | $-4.9M | $-35.3M | ||
| Q2 24 | $-30.2M | $-7.2M | ||
| Q1 24 | $-15.5M | $53.8M |
| Q4 25 | $-52.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-20.0M | — | ||
| Q1 25 | $-31.0M | — | ||
| Q4 24 | $-58.2M | — | ||
| Q3 24 | $-9.4M | $-35.5M | ||
| Q2 24 | $-31.2M | $-7.3M | ||
| Q1 24 | $-15.7M | $53.8M |
| Q4 25 | -60.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -37.6% | — | ||
| Q1 25 | -53.4% | — | ||
| Q4 24 | -125.7% | — | ||
| Q3 24 | -18.2% | -68.7% | ||
| Q2 24 | -63.2% | -9.9% | ||
| Q1 24 | -30.9% | 39.0% |
| Q4 25 | 0.9% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 1.3% | 0.0% | ||
| Q4 24 | 16.3% | 0.0% | ||
| Q3 24 | 8.7% | 0.3% | ||
| Q2 24 | 2.2% | 0.1% | ||
| Q1 24 | 0.4% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -15.80× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.52× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALTI
| Management Advisory Fees | $51.1M | 59% |
| Other | $32.7M | 38% |
| Distributions From Investments | $2.9M | 3% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
